Verici Dx expands kidney transplant research through US clinical trial agreement

Verici Dx Plc

Verici Dx has secured an order from Asahi Kasei Therapeutics to provide blood-based biomarker testing for a Phase 2 clinical trial investigating pegrizeprument, adding a new application for its molecular diagnostic technology in kidney transplantation research.

The agreement will see Verici Dx provide testing that includes its predictive transplant rejection assay (PTRA) as an exploratory research tool. The work is intended to help researchers understand biological responses to treatment and investigate factors that may influence outcomes following kidney transplantation.

The study will assess pegrizeprument, an investigational immunosuppressive therapy being developed for the prevention of acute rejection in solid organ transplant recipients. Verici Dx’s role will be to provide molecular biomarker analysis to support the research programme. The financial value of the order has not been disclosed, and the testing is intended for exploratory research rather than routine clinical decision-making.

The agreement reflects the potential for transplant diagnostics to contribute to pharmaceutical research and development. By examining biological signals in blood samples, researchers can investigate how patients respond to treatment and whether particular molecular patterns are associated with transplant outcomes. Such findings may help inform future research into more personalised approaches to post-transplant care, although the clinical significance of any results will need to be established through further studies.

Verici Dx’s PTRA assay is part of its wider diagnostic offering for kidney transplantation. The company is developing blood-based tests designed to assess biological responses and the risk of transplant rejection. Its Tutivia test is intended to assess the risk of acute rejection following a kidney transplant, providing clinicians with additional information to support patient management.

The company has also welcomed the launch of the US Department of Health and Human Services’ 2026 Kidney Care National Plan. The initiative focuses on preventing kidney failure, improving dialysis care and reforming transplantation.

Verici Dx Plc (LON:VRCI) is developing a complementary suite of proprietary, leading-edge tests forming a kidney transplant diagnostics platform for personalised patient and organ response risk to assist clinicians in medical management for improved patient outcomes. 

Share on:
Find more news, interviews, share price & company profile here for:

Latest Company News

Verici DX reports stronger test adoption and progress towards break-even

Verici DX reported higher test revenue, faster customer adoption and increased orders, while maintaining its target of reaching cash...

Verici Dx targets cash flow breakeven by end of 2027 as US sales expand

Verici Dx is expanding its US sales operation following an £8.75 million fundraising, targeting cash flow breakeven by the...

Kidney Research UK funds new kidney-on-a-chip model to investigate transplant rejection

Kidney Research UK has awarded £110,000 to develop a kidney-on-a-chip model that could help researchers understand transplant rejection, identify...

Verici Dx targets cash-flow breakeven by end of 2027 as Tutivia sales grow

Verici Dx reports 52% year-on-year growth in third-quarter Tutivia orders and targets cash-flow breakeven by the end of 2027....

Verici Dx raises £8.75m through share placing as 2.69bn new shares join AIM

Verici Dx has completed its £8.75m fundraising, with 2.69 billion new ordinary shares admitted to trading on AIM. CEO...

Verici Dx expands kidney transplant research through US clinical trial agreement

Verici Dx has secured an order to provide PTRA and other blood-based biomarker testing for an Asahi Kasei Therapeutics...

Search